GlassScriptPhysician profile
John M Vierling
NPI 1043390388
$269,522.84
in general payments reported to CMS, 2019-2025
24 companies · $79K in 2025
The $79K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $22K · 2021: $21K · 2022: $25K · 2023: $14K · 2024: $55K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Consulting Fee: $55K · Travel and Lodging: $14K · Honoraria: $6,320 · Food and Beverage: $1,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,000.00 |
| Consulting Fee | $55,214.64 |
| Travel and Lodging | $13,972.09 |
| Honoraria | $6,320.00 |
| Food and Beverage | $1,468.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $112,670.33 | 2021-2025 | Livdelzi, Epclusa |
| Alexion Pharmaceuticals, INC. | $26,535.99 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $25,208.61 | 2023-2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $24,358.56 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $23,838.61 | 2019 | |
| Glaxosmithkline, LLC. | $17,760.70 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14,163.15 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,995.50 | 2021-2024 | Entyvio |
| Ipsen Innovation | $3,735.00 | 2022 | |
| Orphalan INC | $3,172.10 | 2023 | Cuvrior |
| Merck Sharp & Dohme LLC | $3,113.51 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,500.00 | 2019 | |
| Amgen INC. | $1,950.00 | 2025 | Uplizna |
| Pfizer INC. | $162.46 | 2019 | |
| Eli Lilly and Company | $154.80 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Wako Diagnostics U.S.A. Corporation | $125.50 | 2019 | |
| Perspectum Diagnostics LTD | $44.60 | 2025 | |
| Abbvie INC. | $33.42 | 2020-2023 | Linzess, Viberzi |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vierling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.